This indicates that the low expression of ESR1, which is known to contribute to endocrine therapy resistance in ER+ breast cancer (Kim et al, 2011), only accounts for few samples displaying low estrogen response activity as detected by Cosinet, and high Cosinet scores do not indicate high ESR1 expression. This evidence concerns the gene ESR1 and breast carcinoma.